Dynamics of immune cell trafficking in interferon-β treated multiple sclerosis patients

Journal of Neuroimmunology

Volumn 139, Issue 1-2, 2003, Pages 84-92

  Hartrich, Laura ^a   Weinstock Guttman, Bianca ^b   Hall, Dennis ^c   Badgett, Darlene ^c   Baier, Monika ^d   Patrick, Kara ^b   Feichter, Joan ^b   Hong, Jianming ^c   Ramanathan, Murali ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b BUFFALO GENERAL HOSPITAL   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d NONE   (United States)

Author keywords

Interferons; Multiple sclerosis; Natural killer cells; Pharmacodynamics; T cells; Trafficking

Indexed keywords

BETA1A INTERFERON; CD69 ANTIGEN; CELL SURFACE PROTEIN;

ARTICLE; B LYMPHOCYTE; BLOOD CELL; CELL ACTIVATION; CELL HETEROGENEITY; CELL POPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MALE; MOLECULAR DYNAMICS; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0037532673     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(03)00135-8     Document Type: Article

References (21)

1. Buchwalder P.A., Buclin T., Trinchard I., Munafo A., Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J. Interferon Cytokine Res. 20:2000;857-866.
2. Calabresi P.A., Tranquill L.R., Dambrosia J.M., Stone L.A., Maloni H., Bash C.N., Frank J.A., McFarland H.F. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann. Neurol. 41:1997;669-674.
3. Calabresi P.A., Prat A., Biernacki K., Rollins J., Antel J.P. T lymphocytes conditioned with Interferon beta induce membrane and soluble VCAM on human brain endothelial cells. J. Neuroimmunol. 115:2001;161-167.
4. Fierlbeck G., Ulmer A., Schreiner T., Stroebel W., Schiebel U., Brzoska J. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma. J. Interferon Cytokine Res. 16:1996;777-781.
5. Floris S., Ruuls S.R., Wierinckx A., van der Pol S.M., Dopp E., van der Meide P.H., Dijkstra C.D., De Vries H.E. Interferon-beta directly influences monocyte infiltration into the central nervous system. J. Neuroimmunol. 127:2002;69-79.
6. Gayo A., Mozo L., Suarez A., Tunon A., Lahoz C., Gutierrez C. Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS [see comments]. Neurology. 52:1999;1764-1770.
7. Jacobs L., O'Malley J., Freeman A., Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science. 214:1981;1026-1028.
8. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E.R., Priore R.I., Pullicino P.M., Scherokman B.J., Whitham R.H.et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG). Ann. Neurol. 39:1996;285-294.
9. Kastrukoff L.F., Morgan N.G., Zecchini D., White R., Petkau A.J., Satoh J., Paty D.W. A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J. Neuroimmunol. 86:1998;123-133.
10. Kastrukoff L.F., Morgan N.G., Zecchini D., White R., Petkau A.J., Satoh J., Paty D.W. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B. Neurology. 52:1999;351-359.
11. Mainiero F., Gismondi A., Milella M., Morrone S., Palmieri G., Piccoli M., Frati L., Santoni A. Long term activation of natural killer cells results in modulation of beta 1-integrin expression and function. J. Immunol. 152:1994;446-454.
12. Munschauer F.E., Hartrich L.A., Stewart C.C., Jacobs L. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J. Neuroimmunol. 62:1995;177-181.
13. Pirelli A., Allavena P., Mantovani A. Activated adherent large granular lymphocytes/natural killer (LGL/NK) cells change their migratory behaviour. Immunology. 65:1988;651-653.
14. Polentarutti N., Bottazzi B., Balotta C., Erroi A., Mantovani A. Modulation of the locomotory capacity of human large granular lymphocytes. Cell. Immunol. 101:1986;204-212.
15. PRISMS 4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 56:2001;1628-1636.
16. Rolstad B., Herberman R.B., Reynolds C.W. Natural killer cell activity in the rat: V. The circulation patterns and tissue localization of peripheral blood large granular lymphocytes (LGL). J. Immunol. 136:1986;2800-2808.
17. Rudick R.A., Ransohoff R.M., Lee J.C., Peppler R., Yu M., Mathisen P.M., Tuohy V.K. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. [published erratum appears in Neurology 1998 Jul;51(1)332] Neurology. 50:1998;1294-1300.
18. Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., Coats M.E., Goodkin D.E., Weinstock-Guttman B., Herndon R.M., Mass M.K., Richert J.R., Salazar A.M., Munschauer F.E. III, Cookfair D.L., Simon J.H., Jacobs L.D. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple sclerosis collaborative research group (MSCRG). Neurology. 50:1998;1266-1272.
19. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:1994;301-314.
20. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;655-661.
21. Yong V.W., Chabot S., Stuve O., Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 51:1998;682-689.